The chemosensitivity to therapy of childhood early B acute lymphoblastic leukemia could be determined by the combined expression of CD34, SPI-B and BCR genes.

We have identified genes differentially expressed in childhood early B acute lymphoblastic leukemia at diagnosis, according to chemosensitivity. Chemosensitive (M1) and chemoresistant (M3) patients present <5% and >25% of residual leukemic blasts at 21 days of treatment, respectively. The expression profiles of 4205 genes for 32 patients included in the FRALLE93 protocol have been determined using microarray. From differential analysis, CD34, SPI-B and BCR distinguished M1 from M3 patients using microarray and RT-PCR data. Linear discriminant analysis (LDA) and cross-validation show that the combined expression of these three genes classify and predict correctly around 90% and 80% of patients, respectively.

[1]  Misao Ohki,et al.  Two distinct gene expression signatures in pediatric acute lymphoblastic leukemia with MLL rearrangements. , 2003, Cancer research.

[2]  J. Harbott,et al.  Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995 , 2000, Leukemia.

[3]  H. Mannila,et al.  Expression of myeloid-specific genes in childhood acute lymphoblastic leukemia – a cDNA array study , 2002, Leukemia.

[4]  Terence P. Speed,et al.  Normalization for cDNA microarry data , 2001, SPIE BiOS.

[5]  J. M. Nørgaard,et al.  Biology of multiple drug resistance in acute leukemia. , 2000, International journal of hematology.

[6]  S. Dudoit,et al.  Multiple Hypothesis Testing in Microarray Experiments , 2003 .

[7]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[8]  G. Getz,et al.  Expression profiles of acute lymphoblastic and myeloblastic leukemias with ALL-1 rearrangements , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  D. Campana,et al.  Childhood acute lymphoblastic leukaemia--current status and future perspectives. , 2001, The Lancet. Oncology.

[10]  Cheng Cheng,et al.  Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. , 2004, The New England journal of medicine.

[11]  H. Cavé,et al.  Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia , 1998 .

[12]  K. Moelling,et al.  The Bcr Kinase Downregulates Ras Signaling by Phosphorylating AF-6 and Binding to Its PDZ Domain , 2003, Molecular and Cellular Biology.

[13]  F. Bertucci,et al.  Sensitivity issues in DNA array-based expression measurements and performance of nylon microarrays for small samples. , 1999, Human molecular genetics.

[14]  Thomas Flohr,et al.  Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. , 2005, Blood.

[15]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[16]  W Hiddemann,et al.  Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients , 2004, Leukemia.

[17]  M J T Reinders,et al.  DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers , 2003, Leukemia.

[18]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[19]  G. Leverger,et al.  Le pronostic des leucémies aiguës lymphoblastiques (LAL) de l'enfant. Résultats du protocole français FRALLE 93. Discussion. , 2001 .

[20]  J. Downing,et al.  Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.

[21]  R. Gentleman,et al.  Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. , 2004, Blood.

[22]  F. Watzinger,et al.  Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program , 2003, Leukemia.

[23]  F. Behm,et al.  Clinical significance of CD34 expression in childhood acute lymphoblastic leukemia. , 1993, Blood.

[24]  T. Hongo,et al.  In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. , 1997, Blood.

[25]  M. Borowitz,et al.  Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a Pediatric Oncology Group study , 1998, Leukemia.

[26]  F. Lanza,et al.  Structural and functional features of the CD34 antigen: an update. , 2001, Journal of biological regulators and homeostatic agents.

[27]  J. Downing,et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.

[28]  P. Musto,et al.  Adult and childhood acute lymphoblastic leukemia: clinico-biological differences based on CD34 antigen expression. , 1997, Haematologica.

[29]  H. Sather,et al.  Early response to therapy and outcome in childhood acute lymphoblastic leukemia , 1997, Cancer.

[30]  O. Majdic,et al.  Signaling and induction of enhanced cytoadhesiveness via the hematopoietic progenitor cell surface molecule CD34. , 1994, Blood.

[31]  A. Órfão,et al.  Clinical and biological significance of CD34 expression in acute leukemia. , 2001, Journal of biological regulators and homeostatic agents.

[32]  S. Granjeaud,et al.  Overexpression of dominant-negative Ikaros 6 protein is restricted to a subset of B common adult acute lymphoblastic leukemias that express high levels of the CD34 antigen. , 2003, The hematology journal : the official journal of the European Haematology Association.

[33]  M. Simon,et al.  SPI-B Activates Transcription via a Unique Proline, Serine, and Threonine Domain and Exhibits DNA Binding Affinity Differences from PU.1* , 1999, The Journal of Biological Chemistry.

[34]  A. Baruchel,et al.  Critical study of prognostic factors in childhood acute lymphoblastic leukaemia: differences in outcome are poorly explained by the most significant prognostic variables , 1998, British journal of haematology.

[35]  A. Órfão,et al.  Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expression , 2001, Leukemia.

[36]  F. Behm,et al.  Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. , 2002, Blood.

[37]  M. Andreeff,et al.  Cell cycle-related shifts in subcellular localization of BCR: association with mitotic chromosomes and with heterochromatin. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Pieters,et al.  Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia , 1991, The Lancet.

[39]  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998 .

[40]  F. Behm,et al.  Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells. , 1994, Blood.

[41]  CD34: structure, biology, and clinical utility. , 1996, Blood.

[42]  R. Kurzrock,et al.  Cytoplasmic and nuclear localization of the 130 and 160 kDa Bcr proteins , 2000, Leukemia.